Molecular genetic studies have revealed CDC73 mutations to be major driver mutations in the etiology of PCs and defining and implementing clinical indications (Table 7) for CDC73 mutation analysis will aid in future management and counseling of patients at risk from PC and PC‐associated syndromes such as HPT‐JT. Here, CDC73 is linked to pachyonychia congenita.